Qiagen reported adjusted earnings of $0.62 per share for the quarter ended December 31, 2025, matching the Zacks Consensus Estimate and coming in just below the prior year’s $0.64 per share. This 3.1% year-over-year decline in per-share profitability reflected modest margin pressure from elevated raw-material and logistics costs, partly offset by disciplined operating expense control. Investors will note that the company’s ability to hold to forecasts under challenging supply-chain conditions underscores the resilience of its core molecular-diagnostics business.

While Qiagen did not disclose full top-line figures in this release, commentary from management indicated that total revenues tracked flat to low-single-digit growth versus the prior quarter, driven by sustained demand for PCR consumables and assays. The Life Sciences segment continued to benefit from academic and industrial R&D budgets, with kit shipments up an estimated 5% year over year. In Molecular Diagnostics, slower hospital and public-health ordering weighed on instrument placements, though assay reagent sales remained stable. Investors should watch for full revenue disclosure in the upcoming 20-F filing to gauge segmental mix shifts.

At SLAS 2026 in Boston, Qiagen publicly unveiled QIAsprint Connect, its first high-throughput benchtop automation system capable of processing up to 192 samples per run. The modular platform features fully customizable workflows via a touch-based interface, reduces plastic consumable waste by up to 50%, and cuts packaging volume by 40%. Management highlighted that the system’s compact footprint and compliance-ready data integrity support (including 21 CFR Part 11) position Qiagen to capture incremental share in research-lab automation. This strategic expansion aligns with the company’s goal of broadening its Sample to Insight ecosystem and driving sustainable long-term growth.